publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
origin
research
thromboembol
chest
effect
rtpa
patient
pte
evalu
dosag
rang
mgkg
min
h
regimen
rtpa
h
approv
us
food
r
ecombin
tissuetyp
plasminogen
activ
rtpa
current
commonli
use
thrombolyt
therapi
pulmonari
thromboembol
pte
similar
thrombolyt
agent
rtpa
carri
signifi
cant
dosedepend
risk
bleed
optim
dose
maxim
benefi
ts
minim
bleed
complic
import
method
prospect
random
multicent
trial
conduct
patient
acut
pte
either
hemodynam
instabl
massiv
pulmonari
arteri
obstruct
randomli
assign
receiv
treatment
regiment
either
rtpa
h
n
h
n
effi
caci
determin
observ
improv
right
ventricular
dysfunct
rvd
echocardiogram
lung
perfus
defect
ventil
perfus
lung
scan
pulmonari
arteri
obstruct
ct
angiogram
advers
event
includ
death
bleed
pte
recurr
also
evalu
result
progress
improv
rvd
lung
perfus
defect
pulmonari
arteri
obstruct
found
similarli
signifi
cant
treatment
group
true
patient
either
hemodynam
instabl
massiv
pulmonari
arteri
obstruct
three
patient
rtpa
h
group
one
rtpa
h
group
die
result
either
pte
bleed
importantli
h
rtpa
regimen
result
less
bleed
tendenc
h
regimen
vs
especi
patient
bodi
weight
kg
vs
p
fatal
recurr
pte
found
either
group
conclus
compar
h
regimen
h
rtpa
regimen
exhibit
similar
effi
caci
perhap
better
safeti
patient
acut
pte
fi
nding
support
notion
optim
rtpa
dose
worthwhil
treat
patient
pte
trial
registr
clinicaltrialsgov
identifi
er
abbrevi
ctpa
comput
tomograph
pulmonari
angiographi
ich
intracrani
hemorrhag
inr
intern
normal
ratio
pte
pulmonari
thromboembol
rtpa
recombin
tissuetyp
plasminogen
activ
rvd
right
ventricular
dysfunct
rvedlv
right
left
ventricular
enddiastol
diamet
ratio
parastern
longaxi
view
rvwm
right
ventricular
wall
movement
spap
systol
pulmonari
arteri
pressur
vq
ventil
perfus
trial
suspend
nearli
year
sever
acut
respiratori
syndrom
outbreak
central
steer
committe
form
charg
studi
design
protocol
develop
standard
qualiti
control
data
verif
analysi
studi
protocol
review
approv
institut
board
ethic
committe
particip
center
patient
enrol
studi
central
randomli
assign
treatment
group
standard
computer
random
program
clinic
inform
imag
patient
review
independ
member
steer
committe
patient
age
year
acut
pte
indic
thrombolyt
therapi
enrol
diagnos
confi
rmed
either
highprob
vq
scan
presenc
intralumin
fi
lling
defect
spiral
comput
tomograph
pulmonari
angiographi
ctpa
examin
patient
symptom
occur
within
day
time
enrol
select
inclus
criteria
either
hemodynam
massiv
pte
patient
hemodynam
instabl
cardiogen
shock
anatom
massiv
pte
patient
massiv
pulmonari
arteri
obstruct
obstruct
two
lobe
ctpa
examin
perfus
defect
seven
segment
vq
scan
combin
rvd
pulmonari
hypertens
echocardiograph
examin
studi
shown
patient
high
risk
fatal
condit
may
benefi
thrombolyt
therapi
patient
exclud
receiv
parenter
heparin
h
thrombolyt
contraind
written
inform
consent
obtain
patient
elig
subject
randomli
assign
receiv
either
mg
rtpa
mg
rtpa
continu
intraven
infus
h
fig
use
rtpa
alteplas
boehring
ingelheim
pharma
shanghai
republ
china
activ
partial
thromboplastin
time
determin
rtpa
infus
valu
subcutan
inject
lowmolecularweight
heparin
nadroparin
antifactor
xa
intern
unitskg
given
everi
h
overlap
oral
anticoagul
therapi
warfarin
start
day
nadroparin
inject
maintain
intern
normal
ratio
inr
nadroparin
stop
day
warfarin
ad
drug
administr
recommend
recent
guidelin
standard
pte
thrombolysi
although
dose
effect
increas
evid
suggest
high
rate
bleed
complic
thu
uncertainti
regard
whether
rtpa
h
regimen
effect
patient
optim
rtpa
dosag
pte
thrombolyt
therapi
lower
dosag
rtpa
h
regimen
use
effect
treat
acut
myocardi
infarct
potenti
fewer
bleed
complic
rtpa
h
may
better
regimen
pte
treatment
well
howev
direct
comparison
rtpa
h
rtpa
h
regimen
conduct
patient
pte
unclear
whether
rtpa
h
regimen
inde
better
dosag
pte
studi
compar
effi
caci
safeti
rtpa
h
rtpa
h
regimen
patient
acut
pte
patient
acut
pte
either
hemodynam
instabl
massiv
pulmonari
arteri
obstruct
right
ventricular
dysfunct
rvd
enrol
effi
caci
assess
improv
right
ventricular
function
echocardiogram
perfus
defect
ventil
perfus
vq
lung
scan
pulmonari
arteri
obstruct
ct
angiogram
advers
event
includ
death
bleed
pte
recurr
also
evalu
analyz
use
repeat
measur
analysi
varianc
subgroup
analysi
also
conduct
base
hemodynam
statu
pte
report
p
valu
twosid
p
consid
statist
signifi
cant
total
patient
screen
multipl
center
nine
patient
inelig
exclud
accord
predefin
exclus
criteria
among
patient
enrol
studi
assign
receiv
mg
rtpa
assign
receiv
mg
rtpa
see
fig
signifi
cant
differ
two
group
regard
baselin
characterist
tabl
improv
pulmonari
arteri
pressur
right
ventricular
function
evalu
echocardiographi
baselin
followup
evalu
rvedlv
rvwm
spap
perform
patient
mg
rtpa
group
mg
rtpa
group
treatment
group
show
signifi
cantli
progress
improv
right
ventricular
function
determin
three
measur
signific
differ
found
two
treatment
group
use
measur
differ
time
point
fig
improv
lung
perfus
determin
vq
lung
scan
baselin
followup
vq
lung
scan
conduct
patient
highdos
group
lowdos
group
treatment
achiev
signifi
cant
improv
pulmonari
vascular
perfus
defect
similar
defect
score
h
day
rtpa
administr
fig
b
improv
pulmonari
arteri
obstruct
assess
ctpa
total
patient
underw
baselin
followup
ctpa
highdos
group
lowdos
group
quantit
assess
show
two
treatment
group
substanti
reduct
pte
obstruct
index
differ
time
point
treatment
signifi
cant
differ
group
fig
c
distribut
signifi
cant
improv
slight
improv
chang
worsen
statu
similar
two
regimen
tabl
mortal
low
group
three
patient
death
highdos
group
two
due
inr
stabil
least
day
warfarin
continu
use
least
month
subsequ
dose
adjust
maintain
inr
within
rang
target
valu
symptom
sign
pte
patient
monitor
echocardiogram
vq
lung
scan
ctpa
evalu
within
h
rtpa
infus
repeat
patient
h
day
rtpa
treatment
effi
caci
determin
observ
improv
right
ventricular
function
echocardiogram
lung
perfus
lung
vq
scan
pulmonari
arteri
obstruct
ctpa
echocardiogram
echocardiograph
examin
perform
analyz
two
echocardiograph
right
ventricular
function
analyz
observ
improv
right
left
ventricular
enddiastol
diamet
ratio
parastern
longaxi
view
rvedlv
right
ventricular
wall
movement
rvwm
estim
systol
pulmonari
arteri
pressur
spap
absenc
left
ventricular
diseas
mitral
valv
diseas
previous
report
vq
lung
scan
lung
scan
independ
review
evalu
two
specialist
use
method
describ
previous
anatom
segment
lung
review
defect
within
segment
score
accord
level
perfus
reduct
locat
sever
thrombu
obstruct
pulmonari
vascular
bed
review
evalu
use
helic
ctpa
score
system
describ
previou
studi
index
defi
ned
product
n
n
valu
proxim
clot
site
equal
number
segment
branch
aris
distal
degre
obstruct
partial
obstruct
score
total
obstruct
grade
advers
event
monitor
day
initi
treatment
rtpa
death
classifi
ed
due
pte
bleed
caus
includ
myocardi
infarct
unknown
caus
major
bleed
includ
case
fatal
bleed
intracrani
hemorrhag
ich
drop
hemoglobin
concentr
least
gl
drop
requir
transfus
ml
rbc
within
h
initi
rtpa
therapi
minor
bleed
includ
case
bleed
hemoglobin
concentr
drop
gl
recurr
pte
confi
rmed
vq
scan
spiral
ctpa
calcul
sampl
size
demonstr
patient
requir
show
differ
point
treatment
group
percentag
reduct
score
ctpa
h
onset
thrombolysi
power
twosid
level
signifi
canc
p
assum
standard
deviat
point
data
analyz
accord
intentiontotreat
principl
categor
data
compar
use
x
test
fisher
exact
test
tabl
comparison
continu
data
treatment
group
perform
use
test
wilcoxon
test
appropri
chang
measur
echocardiogram
vq
lung
scan
ct
pulmonari
angiogram
time
bleed
occur
mg
rtpa
group
mg
rtpa
group
vs
p
one
fatal
bleed
episod
ich
occur
mg
rtpa
group
tabl
three
nonfat
recurr
pte
fi
rst
day
rtpa
therapi
two
patient
mg
rtpa
group
one
mg
rtpa
group
tabl
pte
combin
respiratori
congest
heart
failur
one
due
ich
one
patient
death
lowdos
group
due
pte
combin
respiratori
congest
heart
failur
total
bleed
preval
rel
higher
mg
rtpa
group
compar
mg
rtpa
group
vs
p
major
fig
mg
rtpa
regimen
exhibit
efficaci
mg
rtpa
regimen
pte
thrombolyt
therapi
two
regimen
show
similar
progress
improv
rvd
lung
perfus
defect
pulmonari
arteri
obstruct
patient
either
hemodynam
instabl
massiv
pulmonari
arteri
obstruct
although
overal
preval
death
pte
recurr
similar
two
treatment
mg
rtpa
group
present
less
bleed
especi
lowbodyweight
patient
although
rtpa
shown
effect
treat
acut
pte
optim
regimen
less
defi
ned
sever
studi
indic
lowerdos
rtpa
infus
may
similarli
effect
improv
clinic
present
lung
perfus
defect
pte
compar
convent
rtpa
mg
regimen
consist
studi
studi
clearli
show
rtpa
h
regimen
produc
similar
improv
right
ventricular
function
lung
perfus
defect
pulmonari
arteri
obstruct
compar
rtpa
h
regimen
subgroup
comparison
conduct
separ
patient
hemodynam
instabl
patient
massiv
pulmonari
arteri
obstruct
patient
hemodynam
instabl
mg
rtpa
mg
rtpa
produc
similar
progress
improv
pulmonari
arteri
obstruct
addit
differ
found
two
treatment
term
death
bleed
pte
recurr
patient
tabl
similarli
two
treatment
show
similar
effi
caci
safeti
patient
massiv
pulmonari
vascular
obstruct
compar
effi
caci
safeti
two
dose
regimen
patient
differ
bodi
weight
patient
divid
group
either
tertil
bodi
weight
tertil
bmi
shown
tabl
ctpa
score
differ
data
present
number
patient
improv
pulmonari
arteri
obstruct
baselin
two
treatment
compar
see
tabl
expans
abbrevi
improv
signifi
cant
slight
total
indic
percentag
overal
improv
signifi
cant
improv
obstruct
decreas
slight
improv
obstruct
decreas
chang
obstruct
reduc
wors
obstruct
increas
score
index
thrombolysi
associ
risk
bleed
complic
ich
one
seriou
complic
thrombolyt
therapi
although
practic
use
thrombolyt
therapi
instead
anticoagul
therapi
alon
treat
patient
extens
pulmonari
arteri
obstruct
defi
ned
obstruct
exceed
pulmonari
vasculatur
occlus
two
lobar
arteri
rvd
even
present
normal
system
arteri
pressur
patient
risk
deterior
condit
wors
prognos
studi
shown
patient
may
benefi
thrombolyt
therapi
current
studi
therefor
includ
patient
although
inclus
may
make
effi
caci
comparison
two
regimen
less
conclus
subgroup
analysi
show
mg
rtpa
regimen
effect
patient
massiv
pulmonari
arteri
obstruct
also
patient
hemodynam
instabl
nevertheless
futur
studi
anticoagul
control
patient
massiv
pulmonari
arteri
obstruct
valuabl
determin
whether
thrombolyt
therapi
inde
benefi
cial
patient
comparison
two
dose
regimen
patient
differ
bodi
weight
show
two
treatment
produc
similar
effi
caci
high
medium
lowbodyweight
group
observ
indic
dose
may
reach
therapeut
threshold
similarli
effect
bodyweight
subgroup
patient
howev
addit
analysi
patient
bodi
weight
greater
kg
bmi
greater
kgm
conduct
studi
small
sampl
size
studi
desir
examin
efficaci
mg
regimen
patient
popul
data
present
mean
sd
unless
otherwis
indic
see
tabl
expans
abbrevi
rate
studi
compar
previou
clinic
trial
signifi
cantli
lower
intern
cooper
pulmonari
embol
registri
studi
high
mortal
rate
retrospect
registri
studi
probabl
result
enrol
serious
ill
patient
limit
studi
first
small
sampl
size
common
limit
pte
thrombolyt
studi
prevent
us
achiev
power
effi
caci
safeti
analys
particularli
true
effi
caci
analysi
patient
hemodynam
instabl
patient
higher
bodi
weight
well
mortal
pte
recurr
evalu
patient
futur
studi
larger
sampl
size
desir
examin
effi
caci
safeti
mg
regimen
patient
popul
second
although
physician
evalu
imag
studi
blind
treatment
assign
physician
treat
patient
openlabel
studi
may
potenti
introduc
bia
certain
degre
last
control
group
use
heparin
alon
includ
patient
extens
pulmonari
arteri
obstruct
right
ventricular
dysfunct
futur
studi
use
anticoagul
control
valuabl
determin
whether
thrombolyt
therapi
inde
benefi
cial
patient
differ
statist
signifi
cant
previou
studi
demonstr
preval
ich
rel
higher
patient
receiv
mg
rtpa
studi
observ
overal
bleed
rate
signifi
cantli
lower
mg
rtpa
group
mg
ftpa
group
differ
even
obviou
patient
bodi
weight
kg
bmi
kgm
similar
trend
also
found
major
bleed
rate
major
bleed
studi
compar
previous
report
trial
fi
nding
suggest
rtpa
dose
mg
may
safer
especi
patient
lower
bodi
weight
recommend
dose
safe
use
patient
bodi
weight
kg
studi
larger
patient
popul
would
use
valid
fi
nding
one
major
criterion
evalu
thrombolyt
therapi
pte
recurr
embol
occur
mostli
fi
rst
week
followup
initi
treatment
result
high
mortal
rate
pte
recurr
low
two
therapi
group
one
patient
mg
rtpa
group
two
mg
rtpa
group
consist
previou
studi
although
differ
far
signifi
cant
p
sampl
size
studi
show
mortal
lower
mg
rtpa
group
mg
rtpa
group
seem
result
less
fatal
bleed
less
recurr
pte
mg
rtpa
group
mortal
author
contribut
author
made
substanti
contribut
concept
design
acquisit
data
analysi
interpret
data
review
approv
fi
nal
manuscript
contribut
signifi
cantli
studi
dr
wang
zhai
yang
contribut
equal
work
dr
wang
princip
investig
take
full
respons
integr
submiss
public
involv
studi
design
part
steer
committe
dr
zhai
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
respons
data
verifi
cation
analysi
draft
manuscript
dr
yang
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
dr
wu
respons
patient
enrol
data
collect
dr
z
cheng
respons
patient
enrol
data
collect
dr
liang
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
dr
dai
respons
patient
enrol
data
collect
dr
huang
respons
patient
enrol
data
collect
dr
lu
involv
studi
design
part
steer
committe
dr
zhang
involv
studi
design
part
steer
committe
dr
x
cheng
involv
studi
design
part
steer
committe
dr
shen
respons
data
verifi
cation
analysi
draft
manuscript
financialnonfi
nancial
disclosur
author
report
chest
potenti
confl
ict
interest
exist
companiesorgan
whose
product
servic
may
discuss
articl
contribut
grate
dr
charl
hale
jason
x
j
yuan
lan
zhao
valuabl
suggest
manuscript
